IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study

References

• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–1554.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882.
   PubMed Web of Science ®Google Scholar
• Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999;45 Suppl 4:Iv1–iv11.
   PubMed Web of Science ®Google Scholar
• Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–269.
   PubMed Web of Science ®Google Scholar
• Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782–789 e4.
   PubMed Web of Science ®Google Scholar
• Phillips L, Harp J, Goldstein S, et al. Regulation and action of insulin-like growth factors at the cellular level. Proc Nutr Soc. 1990;49:451–458.
   PubMed Web of Science ®Google Scholar
• Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.
   PubMedGoogle Scholar
• Bonefeld K, Møller S. Insulin-like growth factor-I and the liver. Liver Int. 2011;31:911–919.
   PubMed Web of Science ®Google Scholar
• Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes. 1995;103:63–74.
   PubMed Web of Science ®Google Scholar
• Binoux M. Insulin-like growth factor binding proteins (IGFBPs): physiological and clinical implications. J Pediatr Endocrinol Metab. 1996;Suppl 3:285–288.
   Google Scholar
• Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med Soc Exp Biol Med (New York, NY). 1993;204(1):4–29.
   Google Scholar
• Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res. 1995;6:449–456.
   PubMedGoogle Scholar
• Lang CH, Nystrom GJ, Frost RA. Regulation of IGF binding protein-1 in Hep G2 cells by cytokines and reactive oxygen species. Am J Physiol – Gastrointestinal Liver Physiol. 1999;276:G719–GG27.
   Web of Science ®Google Scholar
• Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res. 1993;12:219–223.
   PubMedGoogle Scholar
• Tsunawaki T, Sakai K, Momomura M, et al. Hypoxia alters phosphorylation status of insulin-like growth factor (IGF)-binding protein-1 and attenuates biological activities of IGF-I in HepG2 cell cultures. J Obstet Gynaecol Res. 2013;39:1367–1373.
   PubMed Web of Science ®Google Scholar
• Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med. 1993;204:4–29.
   PubMed Web of Science ®Google Scholar
• Kotronen A, Lewitt M, Hall K, et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab. 2008;93:4867–4872.
   PubMed Web of Science ®Google Scholar
• Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome – a study in borderline hypertension. Blood Press. 1998;7:89–95.
   PubMedGoogle Scholar
• Li H-H, Doiron K, Patterson AD, et al. Identification of serum insulin-like growth factor binding protein 1 as diagnostic biomarker for early-stage alcohol-induced liver disease. J Transl Med. 2013;11:266.
   PubMed Web of Science ®Google Scholar
• Petäjä EM, Zhou Y, Havana M, et al. Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Sci Rep. 2016;6:24740.
   PubMed Web of Science ®Google Scholar
• Wallander M, Norhammar A, Malmberg K, et al. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and Type 2 diabetes. Diabetes Care. 2007;30:2343–2348.
   PubMed Web of Science ®Google Scholar
• Kalme T, Seppa¨la¨ M, Qiao Q, et al. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90:1550–1556.
   PubMed Web of Science ®Google Scholar
• Petersson U, Ostgren CJ, Brudin L, et al. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra Cardiovascular Risk Factor Study. Diabetes Metab. 2009;35:198–205.
   PubMed Web of Science ®Google Scholar
• Kondoh N, Wakatsuki T, Ryo A, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999;59:4990–4996.
   PubMed Web of Science ®Google Scholar
• Kratzsch J, Blum WF, Schenker E, et al. Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes. 1995;103:285–291.
   PubMed Web of Science ®Google Scholar
• Mesotten D, Delhanty PJD, Vanderhoydonc F, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metabol. 2002;87:5516–5523.
   PubMed Web of Science ®Google Scholar
• Weber MM, Auernhammer CJ, Lee PDK, et al. Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation. Horm Res Paediatr. 2002;57:105–112.
   Web of Science ®Google Scholar
• Donaghy A, Ross R, Gimson A, et al. Growth hormone, insulin like growth factor-1, and insulin like growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology. 1995;21:680–688.
   PubMed Web of Science ®Google Scholar
• Ross RJM, Rodriguez-Arnao J, Donaghy A, et al. Expression of IGFBP-1 in normal and cirrhotic human livers. J Endocrinol. 1994;141:377–382.
   PubMed Web of Science ®Google Scholar
• Shmueli E, Miell JP, Stewart M, et al. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology. 1996;24:127–133.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
   PubMed Web of Science ®Google Scholar
• Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.
   PubMed Web of Science ®Google Scholar
• Bang P, Eriksson U, Sara V, et al. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol. 1991;124:620–629.
   PubMedGoogle Scholar
• Hilding A, Brismar K, Degerblad M, et al. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metabol. 1995;80:2646–2652.
   PubMed Web of Science ®Google Scholar
• Póvoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol. 1984;107:563–570.
   PubMedGoogle Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Unden AL, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin Endocrinol. 2005;63:94–102.
   PubMed Web of Science ®Google Scholar
• Petersson U, Ostgren CJ, Brudin L, et al. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes Metabol. 2009;35:198–205.
   PubMed Web of Science ®Google Scholar
• Lemne C, Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome – a study in borderline hypertension. Blood Press. 1998;7:89–95.
   PubMedGoogle Scholar
• Kotronen A, Lewitt M, Hall K, et al. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metabol. 2008;93:4867–4872.
   PubMed Web of Science ®Google Scholar
• Nedic O, Malenkovic V, Dukanovic B, et al. Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver. Int J Biol Markers. 2008;23:225–230.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yonei Y, Tanaka S, et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:771–781.
   PubMed Web of Science ®Google Scholar
• Cianfarani S, Inzaghi E, Alisi A, et al. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J Pediatr. 2014;165:92–98.
   PubMed Web of Science ®Google Scholar
• Sesti G, Fiorentino TV, Hribal ML, et al. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr Metabol Cardiovasc Dis. 2013;23:1182–1187.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
   PubMed Web of Science ®Google Scholar
• McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269.
   PubMed Web of Science ®Google Scholar
• Chen J-W, Nielsen MF, Caumo A, et al. Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol. 2006;155:285–292.
   PubMed Web of Science ®Google Scholar